Eli Lilly Completes Alnara Pharma Purchase
Eli Lilly & Co. has completed its acquisition of Alnara Therapeutics Inc., a Cambridge, Mass.-based developer of orally-delivered protein therapeutics for the treatment of metabolic diseases. The deal is worth upwards of $380 million, including a $180 million up-ffront payment. Alnara had raised $55 million from MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.
21 July 2010•2 mins read
